Trulieve (TRLV) Q3 2026 Earnings Call Transcript
Trulieve (TRLV) reported Q3 2026 earnings exceeding guidance, with $230M revenue (4% YoY growth), 64% gross margin, and $89M adjusted EBITDA. The company benefited from federal rescheduling of medical marijuana to Schedule III, enabling DEA registration, tax relief, and NYSE listing. Trulieve also repaid $65M in debt, improving cash flow. The company is expanding in Georgia and Texas, with strategic initiatives focused on access, growth, and product portfolio.
How this was made
The 30-second read
Why it matters
The earnings release confirms operational efficiency and benefits from Schedule III status, likely prompting price appreciation.
Market read
First report of Q3 earnings with beat and regulatory tailwinds provides fresh trading catalyst for TRLV.
What to watch
Potential execution risk in new Georgia and Texas expansions and pending further regulatory steps.
Background
Trulieve is the largest U.S. medical cannabis operator, recently uplisted to NYSE after federal rescheduling.
Ticker impact
Trulieve reported Q3 2026 results with $230M revenue, 64% margin and $89M adjusted EBITDA, exceeding guidance.
likely upward pressure as market prices in earnings beat and tax advantage
Strong margins, cash flow and regulatory tailwinds are new and material.
Market effects
Medical cannabis sector may see broader valuation lift from rescheduling and tax changes.
U.S. markets, especially cannabis stocks, could rally on the news.
Limited to U.S. investors; no immediate global macro effect.
Counterpoint
If guidance remains modest, the stock may be overbought after the beat.
Key entities
- companyTrulieve
Largest U.S. medical cannabis operator.
- executiveKimberly Rivers
CEO of Trulieve delivering the earnings call.
